Skip to main content
. Author manuscript; available in PMC: 2018 Aug 21.
Published in final edited form as: Leukemia. 2018 Feb 21;32(6):1421–1426. doi: 10.1038/s41375-018-0063-7

Figure 2.

Figure 2

Progression Free Survival (PFS) based on presence of clonal circulating plasma cells (a) all newly diagnosed AL amyloidosis patients and (b) newly diagnosed AL amyloidosis patients, excluding those with CRAB features

Shown is progression free survival (PFS) based on presence or absence of cPCs at diagnosis in patients with light chain amyloidosis

1, 2 and 5 year progression free survival rates based on presence of cPCs were:

a: cPCs present: 69%, 56% and 23%

cPCs absent: 80%, 74% and 37%

b: cPCs present: 72%, 59% and 26%

cPCs absent: 80%, 74% and 35%